Slide2.PNG (110.18 kB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
2 filesFullscreen
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
posted on 2021-04-13, 14:27authored byAdis journals on behalf of, Philip J. Mease, Apinya Lertratanakul, Kim A. Papp, Filip E. van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W. Keiserman, Xianwei Bu, Liang Chen, Reva M. McCaskill, Patrick Zueger, Erin L. McDearmon-Blondell, Aileen L. Pangan, William Tillett
Article full text
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).